Jonathan Symonds Net Worth

Jonathan Symonds biography

Sir. Jonathan Richard Symonds CBE serves as Independent Director of the Company. Since September 2019, he has been Chairman of GlaxoSmithKline plc. Between April 2014 and February 2020, he was a director of HSBC Holdings plc, a large international banking and financial institution, and was Deputy Group Chairman and senior independent director.Sir Jonathan R. Symonds served as the Chief Financial Officer of Novartis AG from September 2009 to January 2014. Since November 2014, he has served as the Chairman of Proteus Digital Health, Inc., a digital medicine company, and since October 2014, as a director of Genomics England plc, a government organization leading a genomics project, serving as chairman between January 2019 and November 2019. Sir Jonathan R. Symonds served as the Chief Financial Officer of AstraZeneca PLC from October 1997 to July 2007. Sir Jonathan R. Symonds received a B.A. in business finance and an honorary doctorate in law from the University of Hertfordshire. Symonds is qualified to serve on our board of directors because of his experience as a senior finance executive in large publicly held biopharmaceutical companies.

What is the salary of Jonathan Symonds?

As the Independent Director of Rubius Therapeutics Inc, the total compensation of Jonathan Symonds at Rubius Therapeutics Inc is $316,285. There are 9 executives at Rubius Therapeutics Inc getting paid more, with Pablo Cagnoni having the highest compensation of $1,721,130.

How old is Jonathan Symonds?

Jonathan Symonds is 61, he's been the Independent Director of Rubius Therapeutics Inc since 2018. There are 6 older and 12 younger executives at Rubius Therapeutics Inc. The oldest executive at Rubius Therapeutics Inc is Michael Rosenblatt, 69, who is the Independent Director.

What's Jonathan Symonds's mailing address?

Jonathan's mailing address filed with the SEC is C/O RUBIUS THERAPEUTICS, INC., 399 BINNEY STREET, SUITE 300, CAMBRIDGE, MA, 02139.

Insiders trading at Rubius Therapeutics Inc

Over the last 6 years, insiders at Rubius Therapeutics Inc have traded over $2,165,279 worth of Rubius Therapeutics Inc stock and bought 305,000 units worth $6,624,680 . The most active insiders traders include Noubar Afeyan, Roger Pomerantz, and Robert Langer. On average, Rubius Therapeutics Inc executives and independent directors trade stock every 51 days with the average trade being worth of $1,958. The most recent stock trade was executed by Dannielle Appelhans on 24 February 2023, trading 10,385 units of RUBY stock currently worth $1,350.

What does Rubius Therapeutics Inc do?

developing a novel enucleated cell (ecell)(tm) therapy platform for unmet medical needs. founded by flagship venturelabs.

Rubius Therapeutics Inc executives and stock owners

Rubius Therapeutics Inc executives and other stock owners filed with the SEC include:

• Pablo Cagnoni,
  President, Chief Executive Officer, Director
• Maiken Keson-Brookes,
  Chief Legal Officer, Corporate Secretary
• Dr. Pablo J. Cagnoni M.D., Ph.D.,
  CEO, Pres & Director
• David Epstein,
  Chairman of the Board
• Laurence A. Turka M.D.,
  Chief Scientific Officer and Head of Research & Translational Medicine
• Natalie Holles,
  Independent Director
• David R. Epstein B.Sc., M.B.A.,
  Exec. Chairman
• Dannielle Appelhans,
  Chief Operating Officer
• Anne Prener,
  Independent Director
• Jonathan Symonds,
  Independent Director
• Francis Cuss,
  Independent Director
• Catherine Sohn,
  Independent Director
• Noubar Afeyan,
  Independent Director
• Michael Rosenblatt,
  Independent Director
• Lori Melancon,
  IR Contact Officer
• Christina Coughlin,
  Chief Medical Officer
• Greg ..,
  Chief Quality Officer
• Laurence Turka,
  Chief Scientific Officer
• Kris Elverum,
  Senior Vice President - Business Development and Strategy
• Jose Carmona,
  Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer, Treasurer
• Jill Murray,
  VP & Head of HR
• Marissa Hanify,
  Director of Corp. Communications
• Maiken Keson-Brookes,
  Chief Legal Officer & Corp. Sec.
• Elhan Webb C.F.A.,
  VP of Investor Relations
• Mark J. Hernon,
  Chief Information Officer
• Spencer Fisk,
  Sr. VP & Chief Technical Operations Officer
• Jose I. Carmona,
  CFO, Principal Accounting Officer & Treasurer
• Ventures Fund Iv General Pa...,
  
• Susanne Schaffert,
  Director
• Robert Langer,
  Director
• Roger Pomerantz,
  Director
• Ventures Fund Iv General Pa...,
  
• Torben Straight Nissen,
  President
• Christopher L. Carpenter,
  Chief Medical Officer
• Dannielle Appelhans,
  CEO and President